Chronic Graft Versus Host Disease

Georgia B. Vogelsang, MD, is Professor of Oncology at the Johns Hopkins University School of Medicine, Baltimore, Maryland. Steven Z. Pavletic, MD, is the head of the Graft versus Host and Autoimmunity Unit in the Experimental Transplantation and Immunology Branch of the National Cancer Institute, Bethesda, Maryland.

Part I. General Principles: 1. History Alois Gratwohl; 2. Pathophysiology of acute GVHD Carrie Kitko and James L. M. Ferrara; 3. Pathophysiology of chronic GVHD Kirk Schultz; 4. Animal models of chronic GVHD Yu-Wayne Chu, Ronald Gress, and Warren D. Shlomchik; 5. Incidence and trends Sally Arai, Mukta Arora, and Douglas Rizzo; 6. Clinical manifestations and natural history Mary Evelyn D. Flowers and Georgia Vogelsang; 7. Risk factors and predictive models Görgün Akpek and Stephanie J. Lee; 8. Biomarkers in prediction and monitoring Ernst Holler and Anne Dickinson; Part II. Clinical Management: 9. Diagnosis and staging Madan Jagasia, Howard M. Shulman, Alexandra H. Filipovich, and Steven Pavletic; 10. Chronic GVHD pharmacology and commonly used drugs T. Hughes and Timothy McGuire; 11. Prevention of chronic GVHD Andrea Bacigalupo and Nelson J. Chao; 12. Front line treatment of chronic GVHD Paul J. Martin and Andrew L. Gilman; 13. Salvage treatment of chronic GVHD Hildegard T. Greinix and Joseph H. Antin; 14. Response measurement David Jacobsohn, Sandra A. Mitchell, and Steven Z. Pavletic; 15. General principles in ancillary and supportive care Paul A. Carpenter and Dan R. Couriel; Part III. Organ Site or System Specific Manifestations: 16. Skin Edward W. Cowen and Sharon R. Hynes; 17. Mouth Nathaniel S. Treister, Mark M. Schubert, and Jane M. Fall-Dickson; 18. Eyes Stella K. Kim, Janine A. Smith, and James P. Dunn Jr.; 19. Genitalia Maria L. Turner and Pamela Stratton; 20. Gastrointestinal (including nutritional support) Miwa Sakai and George B. McDonald; 21. Pulmonary Javier Bolaños-Meade and Jason W. Chien; 22. Hematologic Corey Cutler; 23. Neurologic Harry Openshaw; 24. Musculoskeletal Li Li, Leighton Chan, and Lynn H. Gerber; 25. Infections Juan Gea-Banacloche and Michael Boeckh; 26. Metabolic and endocrine effects Paul A. Carpenter and Jean E. Sanders; 27. Other manifestations Kristin Baird and Andrew L. Gilman; 28. Psycho-social issues Loretta Williams and Karen L. Syrjala; 29. Secondary and late effects Gérard Socié and H. J. Deeg; 30. Quality of life assessments Sandra A. Mitchell and Bryce B. Reeve; Part IV. Special Considerations in Chronic GVHD: 31. Clinical trials design Paul J. Martin, Donna Przepiorka, and Stephanie J. Lee; 32. Unique clinical situations Mohamad Mohty, Juliet N. Barker, and Claudio Anasetti; 33. Pediatric chronic GVHD Kristin Baird, Alan S. Wayne, and David A. Jacobsohn; 34. Coordination and continuity of interdisciplinary practice Viki Anders, Carina Moravec, and Sandra A. Mitchell; 35. Patient and family education, advocacy, and support groups Kathleen M. Castro, Susan Stuart, Myra J. Jacobs, and Paula Kim; 36. Future directions Stephanie J. Lee.